U.S. Transportation Stock News

Index removals put 10x Genomics in focus for valuation minded investors 10x Genomics (TXG) was removed from several Russell value benchmarks on 27 June 2026, a shift that can influence trading as index tracking funds rebalance and active investors reassess the stock. For you, the key question is whether these index changes simply alter who holds 10x Genomics stock or whether they also change how the market views the company at its recent price levels. See our latest analysis for 10x...

Globus Medical (NYSE:GMED) reports robust revenue growth supported by continued spending on research and development. The company secures new FDA clearances that expand its spine and orthopedic surgery product offering. Recent developments position Globus Medical as a higher growth, innovation driven investment profile compared with Medtronic. Globus Medical, a spine and orthopedics technology company, sits at the center of several long running trends in surgical care, including demand for...

C.H. Robinson Worldwide stock has delivered strong 5 year gains, yet its current valuation checks lean expensive, so investors are weighing sustained optimism against what the numbers say about today’s price. Over the past 5 years, C.H. Robinson Worldwide has returned 128.5%, which puts extra focus on whether the recent strength is already reflected in the share price. The acquisition of DeSpir Logistics for US$75.0m can support long term growth in higher value, security focused freight...

Record highs in the Dow and S&P 500, a powerful chip stock rally, a stronger dollar and softer oil prices are reshaping where risk and opportunity may sit in large caps right now. To help make sense of it, this article focuses on three large cap blue chip stocks from our screener that appear especially exposed to these developments. These stocks may be affected in ways that could be either helpful or challenging, depending on your expectations and time frame. Each stock is backed by sizeable...

First Interstate BancSystem has delivered a 103.8% return over the past three years, and both the intrinsic value estimate from the Excess Returns model and the earnings multiples currently point to the stock trading at a discount to their fair value read, even though the broader valuation checks are more mixed. A 103.8% three year return sets a high bar, so any perceived discount now matters for investors who care about both price and durability of that rerating. Insider selling and recent...

Piper Sandler Companies (NYSE:PIPR) has appointed John D’Amico as a managing director in its restructuring group. D’Amico will focus on complex corporate restructurings and special situations within the firm’s advisory platform. The appointment expands the company’s leadership bench in an area that can be important during more uncertain economic periods. Piper Sandler enters this leadership change with its shares at $71.09 and a mixed recent track record, with the stock down 8.5% over the...

Sterling Infrastructure has delivered a very large 5 year return for shareholders, yet the valuation signals are pulling in different directions, with the Discounted Cash Flow (DCF) intrinsic value estimate implying the stock trades at a premium while earnings based multiples still suggest it screens as undervalued. The stock has returned about 31x over 5 years, which puts extra focus on whether the current price still leaves a margin of safety. Growth expectations around the E...

On 27 June 2026, Flowers Foods was removed from several Russell 1000 and Midcap indices and simultaneously added to the Russell 2000, Russell 2000 Value, and Russell 2000 Defensive indices as part of Russell’s latest index rebalancing. This shift moves Flowers Foods out of large- and mid-cap benchmarks into the small-cap universe, potentially altering which institutional investors and index-tracking funds hold the stock and how they trade it. We’ll now examine how Flowers Foods’ move from...

Over the last 7 days, the United States market has risen by 1.4%, contributing to a robust annual climb of 19%, with earnings forecasted to grow by 19% annually. In this environment, identifying stocks that are potentially trading below their true value can offer investors opportunities for growth as they align with the market's upward trajectory and anticipated earnings expansion.

Over the last 7 days, the United States market has risen by 1.4%, contributing to a 19% increase over the past year, with earnings expected to grow by 19% annually in the coming years. While the term 'penny stock' might seem outdated, it remains relevant as these smaller or newer companies can offer significant opportunities when backed by solid financials. In this article, we'll explore three penny stocks that demonstrate both balance sheet strength and potential for substantial returns,...

Weaker U.S. jobs data has taken some heat out of rate hike fears, lifted gold and reminded investors that policy signals can swing sentiment quickly. For dividend investors, that mix of softer growth signals, sticky inflation risks and another leg up in safe haven demand is a cue to stress test income holdings. This article looks at how that backdrop connects to a hand picked Dividend Stocks screener, focusing on three stocks that stand out for their mix of size, dividend profile and lower...

What the Breakthrough T1D grant means for MannKind The new Breakthrough T1D grant for MannKind (MNKD) and its INHALE-1 study puts Afrezza’s pediatric program in focus, coming shortly after FDA approval for children aged 6 and older. For you as an investor, the grant does two things at once. It validates Afrezza as a research priority within the type 1 diabetes community, and it helps support clinical work that MannKind would otherwise need to fund on its own. The INHALE-1 trial is centered on...

In late June 2026, Rapport Therapeutics, Inc. was added to several Russell growth and small-cap benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indices. This broad inclusion across multiple Russell growth and microcap indices can significantly raise the company’s profile among institutional and index-tracking investors. Next, we’ll explore how this broad Russell index inclusion could influence Rapport Therapeutics’ investment narrative, particularly around...

Knife River (KNF) has been removed from both the Russell 2000 Defensive Index and the Russell 2000 Growth-Defensive Index, a change that can influence index fund flows and short term trading interest. See our latest analysis for Knife River. Knife River’s removal from the Russell 2000 Defensive indexes comes after a mixed stretch in trading, with the stock down 8.63% on a 7 day share price return but still showing a 16.69% year to date share price return and a 3 year total shareholder return...

In recent coverage of Federal Agricultural Mortgage, analysts highlighted how its diversified segments across Farm & Ranch, Corporate AgFinance, and Infrastructure Finance helped it handle industry headwinds from elevated mortgage rates while delivering double-digit year-over-year gains in business volume, revenues, and core earnings earlier in 2026. An interesting angle is how this multi-segment footprint in rural America, combined with disciplined underwriting and steady customer demand,...

Mobility Global (MBGL) has just completed its spin off from S&P Global, with shares distributed to existing S&P Global investors and trading beginning on the New York Stock Exchange on July 1, 2026. See our latest analysis for Mobility Global. After the spin off, Mobility Global’s 1 day share price return declined 6.56% and its year to date share price return is down 5.69%. This suggests early trading pressure even as the stock joins multiple global indices and completes a broad board...

Earlier this week, Congress passed the bipartisan 21st Century ROAD to Housing Act, a housing-focused law that investors expect to support construction-related businesses such as Installed Building Products. The legislation’s emphasis on addressing housing demand has drawn attention to companies leveraged to commercial and multifamily construction, spotlighting Installed Building Products’ positioning across these segments. Next, we’ll examine how the new housing law’s focus on demand and...

Why Harrow stock is in focus after the BYOOVIZ launch Harrow (HROW) is back on investors’ radar after launching BYOOVIZ in the US, a Lucentis biosimilar that carries FDA interchangeability status for several retinal conditions tied to anti VEGF treatment. See our latest analysis for Harrow. Harrow’s official BYOOVIZ launch comes after a sharp 28.27% 1 month share price gain and a 21.04% 3 month share price return, while the year to date share price is still down 14.37%. Over the longer term,...

In late June 2026, Lantheus Holdings reported that the FDA issued a Complete Response Letter for its LNTH-2501 PET imaging kit for somatostatin receptor‑positive neuroendocrine tumors, citing unresolved third‑party manufacturing facility issues rather than concerns about the product’s safety, efficacy, or supporting data. Separately, the company was added to both the Russell 2000 Defensive Index and the Russell 2000 Growth‑Defensive Index, highlighting its growing profile within defensive...

Marex Group plc recently completed its redomiciliation from England and Wales to Bermuda, following shareholder approval, global regulatory clearances, and sanction by the English High Court, with the move becoming effective on 1 July 2026. This shift places Marex under Bermuda’s US-style corporate law, aligning more closely with its Nasdaq listing and aiming to simplify its structure and reduce operating costs. We’ll now examine how Marex’s move to Bermuda, alongside its removal from...

In late June 2026, StoneCo Ltd. (NasdaqGS: STNE) was added to multiple Russell value indexes, including the Russell 2000, 2500, 3000, 3000E and Small Cap Comp Value benchmarks. This wave of index inclusions coincides with upbeat analyst expectations ahead of StoneCo’s upcoming earnings release, including a favorable Zacks Rank of #2 (Buy) and projected earnings and revenue growth. We’ll now examine how this combination of index additions and upbeat analyst sentiment may influence StoneCo’s...

CNA Financial (CNA) has drawn attention after its stock rose 3.1% on July 2 to $51.17, trading modestly above one valuation estimate while carrying an Above Average GF Score of 63/100. See our latest analysis for CNA Financial. The recent 3.1% move adds to a strong run for CNA Financial, with a 30-day share price return of 21.14% and a 1-year total shareholder return of 21.52%, indicating momentum that contrasts with moderate concerns flagged in its GF Score. If this kind of sustained...

Premium credit cards are turning into lifestyle passes, with American Express, Chase and rivals racing to win affluent cardholders through airport lounges, event access and higher tier perks. With annual fees at the top end now reaching hundreds of dollars, the gap between premium and mass market customers is widening, and fee income is becoming more concentrated among high spenders. This article looks at three stocks from our Premium Consumer Finance Stocks screener that appear especially...

In recent weeks, First Advantage reported first-quarter 2026 results that exceeded analyst expectations and confirmed its upcoming inclusion in the S&P SmallCap 600 index, reinforcing its profile within the employment screening and digital identity market. This combination of an earnings beat and index addition underscores how operational outperformance and higher index visibility can reshape how investors view First Advantage’s role in outsourced verification services. Now, we’ll explore...